Barbara Rothbaum, Lynnette A. Averill
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Dr. Anne Wagner and Dr. Michael Mithoefer discuss therapeutic potential of MDMA for couples, sharing insights from their MDMA-assisted couples therapy trials and ongoing research with Dr. Chandra Khalifian and
Chandra Khalifian, Leslie Morland, Kayla Knopp
MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.
Adele LaFrance, Timothy Brewerton
Dr. Smith and Dr. Jones explore the latest research on psychedelic therapy and its potential impact on mental health during the PS2023 conference.
Stacy Fischer, Anthony “Tony” Bossis, Charles S Grob, Manish Agrawal, Shoshana Ungerleider
Study aims to re-examine inhaled cannabis for treating PTSD, with Phase 2 study assessing high THC cannabis versus placebo for managing symptoms and pain in 360 veterans across U.S.
Sue Sisley, Shane Pennington
Neurological disorders like chronic pain and Alzheimer’s are being studied for psychedelic therapy benefits, expanding research beyond traditional mental health applications. Current studies explore potential applications for neurorehabilitation.
Julia Bornemann, James Close, Joel Castellanos, Robin Carhart-Harris
MDMA's therapeutic mechanism differs from classical psychedelics, showing potential for treating CNS disorders. Shulgin's 1970s research inspired exploration of modifying MDMA's structure and developing novel compounds for improved effects.
Matthew Baggott
KAP program offers innovative treatment for adolescents with emotional issues, focusing on family involvement. Successes and challenges of this unique approach are discussed.
Phil Wolfson
MDMA optimizes brain chemistry for safety, openness, and compassion. AEDP uses relational interventions to enhance MDMA's effects in trauma therapy, fostering trust, intimacy, and healing attachment.
Kari Gleiser
Executives of major psychedelic drug developers discuss building infrastructure for psychedelic therapy in healthcare, including education, clinics, EMR tools, and research to enhance outcomes.
Doug Drysdale
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.